Mach7 Technologies Q4 FY26 Business Update
Key points
- Positive operating cash flow of A$1.1M in Q4 FY26
- Cash of A$19.9M at 30 June 2026, up 4% vs end Q3 FY26
- ARR run rate of A$23.5M at 30 June 2026, up 7.6% in constant currency vs 30 June 2025
- New 5-year A$2.8M TCV subscription with a leading academic medical centre
- eUnity listed in Epic Connection Hub, enhancing interoperability
Full summary
Mach7 Technologies Limited, a healthcare software company, provided a business update for Q4 FY26. Key highlights include a positive operating cash flow of A$1.1M in Q4 FY26, a cash balance of A$19.9M at 30 June 2026, and an ARR run rate of A$23.5M, up 7.6% in constant currency. The company signed a new 5-year A$2.8M TCV subscription with a leading academic medical centre and achieved a key milestone with eUnity listed in Epic Connection Hub. Mach7 also expanded its partner ecosystem, notably with Howard Medical, and completed the first production deployment of Flamingo with UnityPoint Health. The company reaffirmed its FY26 guidance, expecting revenue to be approximately 15% below FY25 due to delayed capital deal conversion, with operating expenses expected to be approximately 10% lower.
Guidance
FY26 revenue expected to be approximately 15% below FY25; operating expenses expected to be approximately 10% lower
Outlook
Mach7 is focused on restoring operational discipline, building high-quality recurring revenue, and laying the foundation for sustainable growth. The company continues to invest in Flamingo, AI, and commercial capability to support FY27 growth.
Summary generated by a large language model. Please interpret with care.